Literature DB >> 24148073

Paraneoplastic cerebellar degeneration caused by ovarian clear-cell carcinoma.

Y Negishi1, K Sakai, Y Noguchi, N Iwasaki, N Kawai.   

Abstract

Paraneoplastic cerebellar degeneration is a paraneoplastic neurological syndrome caused by the remote effect of certain systemic cancers and is characterized by subacute cerebellar symptoms. A 62-year-old woman suffering from unidentified cerebellar symptoms was admitted to our hospital. Paraneoplastic cerebellar degeneration was suspected and ovarian cancer was detected after the systemic examination for malignancy. The symptoms of vertigo and dysarthria were improved a little after surgical operation and treatments of γ-globulin, steroid pulse and tacrolimus hydrate. The cerebellar symptoms of paraneoplastic cerebellar degeneration are often evident prior to detection of malignancy. It is important to perform systemic examination for malignancy in case of unidentified cerebellar symptoms.
© 2013 The Authors. Journal of Obstetrics and Gynaecology Research © 2013 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  Yo antibody; ovarian cancer; paraneoplastic cerebellar degeneration; paraneoplastic neurological syndrome; tacrolimus hydrate

Mesh:

Substances:

Year:  2013        PMID: 24148073     DOI: 10.1111/jog.12212

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  3 in total

1.  Paraneoplastic Cerebellar Degeneration-A Rare Presentation of Ovarian Malignancy.

Authors:  Richa Sharma; Gita Radhakrishnan; A G Radhika; Anshuja Singla
Journal:  J Obstet Gynaecol India       Date:  2015-08-22

2.  Anti-Yo positive and late-onset paraneoplastic cerebellar degeneration associated with ovarian carcinoma: A case report.

Authors:  Dan Cui; Li Xu; Wen-Yi Li; Wei-Dong Qian
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

Review 3.  Paraneoplastic neurological syndromes associated with ovarian tumors.

Authors:  Mikolaj Piotr Zaborowski; Marek Spaczynski; Ewa Nowak-Markwitz; Slawomir Michalak
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.